Will Merck’s New Drug Crack the Alzheimer’s Code?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn


A drug designed by Merck (NYSE:MRK) may be the next big thing in treating patients with Alzheimer’s disease, The Wall Street Journal reports. MK-8931 is the technical name of a drug that is currently being tested on those with the disease known for crippling the memories of older people. In a Phase II/III EPOCH study currently underway, so far, the Data Monitoring Committee has not had bad things to say about the results and effects of the drug.

In fact, the committee has given Merck the green light to go ahead with a Phase III APEC study, which will test the impact of the drug on those who already have some levels of impairment from the disease. The group noted that Merck will continue to admit patients to the EPOCH study, the results of which are yet to be completed in its entirety. However, the data available up to this point look promising, and there is no reason for concern in moving onward with the testing process of the drug, according to the company.

MK-8931 targets the buildup of beta amyloid in the brain. Beta amyloid is a sequence of amino acids that accumulates in the brain to form amyloid plaques, the masses of particles that build up in patients with Alzheimer’s, the Journal reports. Those plaques can then have negative consequences for mental functions. Though there are many ways to target beta amyloid that occur naturally in the body, so far researchers have been unable to effectively design a drug to combat the substance — that is, perhaps up until now.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business